Share:

Posted on 10 December 2018

Clovis Oncology has announced that the European Patent Office (EPO) last week upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate, including rucaparib S-camsylate Form A, the crystalline form in Rubraca.

In its oral decision announced at a hearing on 4 December, the Opposition Division upheld claims, narrowed from the originally granted patent, to certain crystalline forms of rucaparib camsylate. These forms include, but are not limited to, the commercial product. The European Opposition Division found patentability of the claimed forms based on the inventiveness of these crystalline forms and a constellation of unexpected properties.

Partner Richard Clegg and Associate Sarah Kostiuk-Smith represented Clovis Oncology at the opposition proceedings at the EPO.

Richard Clegg said, “This is a great result for Clovis Oncology and one that acknowledges the innovation behind Rubraca. We are delighted to have been able to ensure the continued success of this ground-breaking cancer treatment.”

 

Richard Clegg

Contact Richard Clegg

Richard is a member of our life sciences patent team and has particular experience in the biotechnology and pharmaceutical sectors. He has a diverse patent practise, working closely with clients in the UK, Europe and Singapore to prepare patent applications and prosecute them to grant on a global basis. He also works with many US clients to obtain European patents before the EPO and defend them in EPO opposition/appeal proceedings. Since 2003, Richard has been heavily involved in obtaining European patents for aptamer (SELEX) technology and succeeded in obtaining grant of the very first aptamer patents in Europe. Richard also has considerable involvement with start-up and spin out companies, including transition of patent portfolios from technology transfer into nascent companies. In addition to patent prosecution, this often involves generating and implementing an ongoing freedom to operate strategy for the company and conducting IP due diligence for the purpose of helping the company raise investment. Richard has provided in-house support to some SME clients, spending time in the R&D department to spot inventions and generate new patent applications.

Related Posts